Healthcare company Sanofi announces share buyback of up to 2 billion euros
French healthcare company Sanofi announced on Friday a share buyback plan worth up to 2 billion euros ($2.1 billion), which ...
The Pharma Letter13h
FDA Priority Review for Insmed's brensocatib for bronchiectasis
The US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for brensocatib for patients with ...
FiercePharma14h
Regeneron tangles with Sanofi over commercial transparency in long-running Dupixent collaboration
Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...
The Pharma Letter23h
NEJM publishes Bizengri data after speedy FDA nod
The New England Journal of Medicine has published results from the Phase II eNRGy trial for Bizengri (zenocutuzumab), a novel cancer med from Merus. Bizengri is the first approved treatment for people ...